Please ensure Javascript is enabled for purposes of website accessibility
Exelixis Stock Quote

Exelixis (NASDAQ: EXEL)

Price as of June 9, 2023, 3:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Exelixis Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
EXEL +0.68% -0.31% -0.06% +27%
S&P +2.57% +53.56% +8.96% +184%

Exelixis Company Info

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

News & Analysis

The Fool has written over 500 articles on Exelixis.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.